Literature DB >> 1358394

Cannabis and psychotic illness.

D C Mathers1, A H Ghodse.   

Abstract

In-patients with psychotic symptoms and cannabis-positive urine analysis were assessed by PSE within one week of admission and again at one and six months. Concurrently admitted psychotic patients with drug-free urine analysis were controls. At one week the two groups differed significantly on only five PSE items: changed perception, thought insertion, non-verbal auditory hallucinations, delusions of control, and delusions of grandiose ability. One item (delayed sleep) differed at one month, and none at six months. The symptom cluster at one week is consistent with acute cannabis intoxication. Subjects and controls were mostly single, poorly educated, unemployed people with histories of psychotic disorders, and given major tranquillisers on admission. Compared with controls, subjects were younger, less likely to have psychiatric histories, more often male, Afro-Caribbeans with a history of convictions and compulsory admissions. The commonest diagnosis was schizophrenia. Use of the label 'cannabis-induced psychosis' may obscure a diagnosis of paranoid schizophrenia. A short-lived psychotic episode does occur in clear consciousness after cannabis intoxication, but chronic cannabis-induced psychosis was not found.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358394     DOI: 10.1192/bjp.161.5.648

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  17 in total

Review 1.  Improving the quality of the cannabis debate: defining the different domains.

Authors:  J Strang; J Witton; W Hall
Journal:  BMJ       Date:  2000-01-08

Review 2.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

3.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

4.  Cannabis related psychiatric syndromes: a selective review.

Authors:  D Basu; A Malhotra; V K Varma
Journal:  Indian J Psychiatry       Date:  1994-07       Impact factor: 1.759

5.  (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population.

Authors:  Isabel Martínez-Gras; Janet Hoenicka; Guillermo Ponce; Roberto Rodríguez-Jiménez; Miguel Angel Jiménez-Arriero; Elena Pérez-Hernandez; Israel Ampuero; Jose Antonio Ramos-Atance; Tomas Palomo; Gabriel Rubio
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-20       Impact factor: 5.270

6.  Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use.

Authors:  Romina Mizrahi; Miran Kenk; Ivonne Suridjan; Isabelle Boileau; Tony P George; Kwame McKenzie; Alan A Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2013-12-24       Impact factor: 7.853

Review 7.  Cannabis-associated psychosis: current status of research.

Authors:  F Markus Leweke; Christoph W Gerth; Joachim Klosterkötter
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

9.  Concurrent and Sustained Cumulative Effects of Adolescent Marijuana Use on Subclinical Psychotic Symptoms.

Authors:  Jordan Bechtold; Alison Hipwell; David A Lewis; Rolf Loeber; Dustin Pardini
Journal:  Am J Psychiatry       Date:  2016-05-03       Impact factor: 18.112

10.  Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO.

Authors:  Romina Mizrahi; Ivonne Suridjan; Miran Kenk; Tony P George; Alan Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.